Condition: Advanced or Metastatic Adrenocortical Carcinoma · Metastatic Castration-resistant Prostate Cancer · Sponsor: Daiichi Sankyo
This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Brown University | Providence, Rhode Island, United States | Recruiting |
| Oncopole Claudius Regaud | Toulouse, France | Recruiting |
| Centre Oscar Lambret | Villejuif, France | Not Yet Recruiting |
| Royal Marsden | London, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07189403